Although USF-1 and -2 are the major proteins that bind to Myc-regulated E-box (CACGTG) elements in many cells, there is no clear role for USF during Mycdependent gene regulation. Using dominant negative alleles of USF-1 we now show that DNA binding by USF at a Myc-regulated E-box limits the ability of another E-box binding factor, TFE-3, to activate a target gene of Myc in vivo and to stimulate S phase entry in resting ®broblasts. Similarly, dominant negative alleles of USF-1 relieve the restriction that prevents activation of the IgH enhancer by TFE-3 in non B-cells. DNA binding activity of USF complexes is abundant in primary human B-cells and is signi®cantly downregulated during B-cell immortalization. Re-expression of USF-1 in immortalized B-cells retards proliferation. Our data establish an essential role for USF in restricting E-box dependent gene activation in vivo and suggest that this control is relaxed during cellular immortalization.
Introduction
The proto-oncogene c-myc encodes a transcription factor of the helix ± loop ± helix/leucine zipper family. The gene product, Myc, binds to speci®c DNA sequences termed E-boxes with a central CAC(A/ G)TG sequence as part of a heterodimeric complex with a partner protein, Max. The heterodimeric complex is a potent activator of transcription due to activation domains located in the amino-terminus of the Myc protein. Max also heterodimerizes with a second group of related proteins termed Mad-1, Mxi-1, Mad-3, Mad-4 and Mnt/Rox: these complexes bind to the same sequences on DNA but, in contrast to Myc/ Max complexes, generally repress transcription (for a detailed review, see Henriksson and LuÈ scher, 1996) .
Repression requires an amino-terminal domain conserved in Mad-like proteins that recruits histone deacetylases via an adapter protein, sin3 (e.g. Alland et al., 1997; Laherty et al., 1997; Sommer et al., 1997) .
Little doubt exists that Myc exerts at least part of its biological eects through the transcriptional activation of speci®c target genes although Myc has other functions that may contribute to its biological properties (Xiao et al., 1998) . Indeed, several target genes of Myc are known that can account for some of the biological properties of Myc (for review, see Grandori et al., 1997) .
A number of transcription factors closely related to Myc also bind to CAC(A/G)TG sequence elements and activate transcription; examples include USF-1 and -2 (e.g. Sirito et al., 1998) , TFE-3 (Beckmann et al., 1990) and TFEB (Fisher et al., 1991) . Fusion of the aminoterminal repression domain of Mad-1 to TFEB generates a protein that is capable of suppressing cellular transformation by Myc, demonstrating that these proteins have overlapping binding sites on DNA in vivo (Harper et al., 1996) . Despite their biochemical similarities, the biological functions of the dierent Ebox binding factors dier widely. For example, ectopic expression of Myc, but not USF-1 or TFE-3, induces proliferation and apoptosis in RAT1 ®broblasts (for review, see Bouchard et al., 1998) (A Kiermaier, unpublished) . Conversely, inhibition of Myc function often causes an inability of cells to proliferate but loss of TFE-3 function in B-cells causes a defect in activation, but not proliferation (Merrell et al., 1997) . Most likely, therefore, mechanisms exist that discriminate between these closely related factors during activation of endogenous target genes.
Several genes have been identi®ed that are speci®cally activated by single members of this family of transcription factors. Examples include prothymosin-a (Desbarats et al., 1996) , ornithine decarboxylase (ODC) (Tobias et al., 1995) and CAD (Boyd et al., 1998) that are speci®cally activated by Myc, and the immunoglobulin (IgH) enhancer which is transactivated by TFE-3 only in B-cells (Carter et al., 1997) .
Speci®c mutations in the prothymosin-a gene allow activation by TFE-3; similarly, mutations in the IgH enhancer allow activation by TFE-3 in non B-cells, demonstrating that TFE-3 is actively prevented from activating these genes in vivo (Desbarats et al., 1996; Genetta et al., 1994) . We now demonstrate that DNA binding by USF is required for inhibiting transactiva-tion by TFE-3 in vivo. Our results de®ne a novel and unexpected role for the transcription factor USF in restricting inappropriate activation of E-box dependent gene activation in vivo and suggest that this control is relaxed during cellular immortalization.
Results
Previous work has shown that ectopic expression of TFE-3 failed to activate the IgH or prothymosin-a enhancers; in both cases, a mutation in a second E-box element close to the TFE-3 binding site relieved the restriction, suggesting that factors binding to these elements actively prevent transcriptional activation by TFE-3 (Desbarats et al., 1996; Genetta et al., 1994) (Figure 1a) . In order to test whether this restriction targets the transcriptional activation domain of TFE-3, we generated a chimeric protein that carries the transactivation domain of the viral Vp16 protein and a nuclear localization signal of SV40 large T antigen fused to the open reading frame of TFE-3 (Figure 1b ). Plasmids encoding this chimera under the control of the CMV immediate early promoter were transfected into HeLa cells together with a reporter plasmid that carries four E-box elements in front of a minimal promoter ((E-box) 4 -tkluc). Vp16-TFE-3 strongly activated this promoter ( Figure 1b) ; a mutant derivative, in which the E-boxes had been altered to CACTCA, (E-boxmut) 4 -tkluc, was not activated by Vp16-TFE-3. In contrast, Vp16-TFE-3 was unable to activate a reporter plasmid in which 36 bp surrounding the Mycregulated E-box from the prothymosin-a gene (E1) had been placed in front of a minimal promoter (36E-tkluc; Figure 1a ). This is surprising, as recombinant TFE-3 binds to this site with high anity in vitro (Desbarats et al., 1996) . Mutation of the second E-box element (E2) in this 36 bp enhancer fragment (in mutE2-tkluc) allowed both TFE-3 ( Figure 1a ) and Vp16-TFE-3 to activate prothymosin-a (Figure 1b) . The experiment shows that the failure of TFE-3 to induce expression of prothymosin-a is neither due to a particular transactivation domain nor due to inecient nuclear import of TFE-3.
In a second experiment, we tested whether the restriction required an intact TFE-3 binding site. To do so, we generated a prothymosin-a reporter in which the TFE-3/Myc/USF (E1) binding site was disrupted by insertion of an oligonucleotide containing a GAL4 binding site (Figure 1c ). The mutated reporter was activated by a GAL4-TFE-3 chimeric protein in which the transactivation domain of TFE-3 was fused to the DNA binding domain of the yeast transcription factor GAL4 even in the context of the wild-type prothymosin-a reporter. Mutation of the E2 site within this context somewhat enhanced activation by GAL4-TFE-3. The experiment shows that repression of activation by TFE-3 and Vp16-TFE-3 is largely dependent on an intact TFE-3/Myc/USF (E1) site.
The prothymosin-a gene diers from synthetic reporter constructs in that the TFE-3/Myc/USF binding site is part of an enhancer element with multiple conserved factor binding sites. DNAase I footprint experiments demonstrated that multiple elements are protected by nuclear extracts from HeLa cells in addition to the known binding sites for Myc/ Max and AP-2 proteins (see Gaubatz et al., 1995 and Figure 2a) ; in particular, the E2 element is protected by nuclear extracts, but not by USF-1, AP-2 or Max.
One potential mechanism by which factors binding to E2 could restrict activation by TFE-3 is by stabilizing cellular factors that bind to the TFE-3/ Myc/USF-binding site. Since USF proteins constitute the most abundant E-box binding activity, we speculated that USF may have a function in restricting activation of target genes of Myc. To test the hypothesis that USF interacts with a Myc-activated E-box in vivo, chromatin immune-precipitation experiments were carried out. RAT1-MycER cells were harvested and proteins cross-linked to DNA by exposure to UV-light. Cross-linked DNA was immune-precipitated with anti-Myc, Max or USF antibodies, or as control, protein-A-sepharose alone. The immune-precipitates were subjected to a polymerase-chain reaction using nested primers that amplify a fragment surrounding E1 and E2 (Figure 2b ). We detected binding of all three proteins, Myc, Max and USF to the genomic fragment containing the prothymosin-a TFE-3/Myc/USF binding site in vivo. Similar results have recently been obtained for the Myc-regulated E-Box of the CAD gene (Boyd et al., 1998) .
To assess the potential function of USF, we generated dominant negative alleles that interfere with DNA binding by USF and by Max (Figure 3a) . For each protein, the amino-terminus up to and including the basic region was deleted, generating USF-1Dbr and MaxDbr. For USF-1 (but not Max), this deletes the nuclear import signal and therefore a nuclear import signal derived from SV40 was fused to the aminoterminus of USF-1Dbr for expression in mammalian cells. In a second mutant, amino acids predicted to make critical DNA contacts based on the crystal structures of USF-1 (FerreÂ D'AmareÂ et al., 1994) and Max (FerreÂ D'AmareÂ et al., 1993) were mutated, generating USF-1mutbr and Maxmutbr ( Figure 3a) .
To exclude the possibility that deletion or mutation of the basic region of USF-1 generates aberrantly folded proteins, we puri®ed recombinant His-tagged proteins of both wtUSF-1 and of USF-1Dbr after expression in E. coli ( Figure 3b ). In electrophoretic mobility shift assays (EMSA), wtUSF-1, but not USF1Dbr bound to the E1-element from the rat prothymosin-a gene ( Figure 3c ). The identity of the shifted band was con®rmed using speci®c antibodies directed against USF. Preincubation of wtUSF-1 with USF-1Dbr inhibited DNA-binding by wtUSF-1 in a dose-dependent manner. We conclude that mutation of the basic region generates ecient dominant negative alleles of USF.
To test whether DNA binding by USF is required to restrict activation by TFE-3, USF-1mutbr or USF1Dbr were co-expressed with TFE-3 and a reporter plasmid derived from prothymosin-a, 36E-tkluc ( Figure  4a ,c). Neither TFE-3 nor USF-1mutbr or USFDbr signi®cantly activated the 36E-tkluc reporter by itself ( Figure 4 ). In contrast, co-expression of TFE-3 with either dominant negative allele of USF-1 led to signi®cant activation of the prothymosin-a reporter. TFE-3 alone activated the mutE2-tkluc reporter, and this was unaected by co-expression of USF-1mutbr
Figure 1 TFE-3 is unable to activate prothymosin-a even when provided with a strong transactivation domain and a nuclear import signal. (a) Reporter constructs used in the experiments. The Myc/USF/TFE-3 binding site is shown in black and designated E1 in the prothymosin-a gene and E3 in the IgH enhancer. The ability of these constructs to be activated by TFE-3 in non B-cells is summarized. (b) Results of transient transfection assays using the NLS-Vp16-TFE-3 or control Vp16 expression plasmid and the indicated reporter constructs in HeLa cells. (c) Activation by GAL4-TFE-3 of a prothymosin-a derived reporter construct in which E1 is disrupted by insertion of a GAL4 binding site and the E2 site is intact (GAL4/E2) or mutated (GAL4/mutE2) ( Figure 4a ). Neither TFE-3 nor USF-1mutbr activated a reporter in which both E-boxes were disrupted (mut E1/E2) con®rming that activation is dependent on an intact E1 site (Figure 4a ).
In the genomic-sequence of prothymosin-a, the Mycresponsive E-box element (E1) is located 2 kb downstream from the start site of transcription (Gaubatz et al., 1995) . We therefore repeated the experiment using a reporter plasmid in which the entire gene up to exon 2 is fused inframe to luciferase coding sequences within exon 2 (ProT-luc) ( Figure 4a ). Neither USF1mutbr nor TFE-3 signi®cantly activated the reporter alone, yet together up to 50-fold activation occurred. This is in agreement with previous observations that the transactivation domain of TFE-3, but not USF-1, is capable of activation from a promoter-distal position (Desbarats et al., 1996) .
Three additional controls demonstrated the speci®city of the activation conferred by dominant negative USF-1 alleles. First, dominant negative alleles of USF-1 did not aect transactivation by GAL4-TFE-3 of a prothymosin receptor plasmid in which E1 is disrupted by insertion of a GAL4-binding site (Figure 1b) . Second, such alleles did not signi®cantly aect transactivation of prothymosin-a by Myc (Figure 4b ). Third, dominant negative alleles of Max did not synergize with TFE-3 in activation (data shown for MaxDbr in Figure 4c ). Western blotting con®rmed high levels of expression of the dominant negative alleles of Max (data not shown). Two other putative target genes of Myc were also tested. We observed signi®cant activation of ODC reporters (Bello-Fernandez et al., 1993) by TFE-3 alone which was enhanced moderately by USF1mutbr. For RCC-1 (Tsuneoka et al., 1997) we did not observe activation by any transcription factor in our assays (data not shown).
A second gene for which speci®c activation has been demonstrated is the B-cell speci®c immunoglobulin heavy chain (IgH) enhancer. In analogy to the situation of prothymosin-a, TFE-3 is unable to activate the enhancer in non B-cells due to the presence of an inhibitory E-box (E5) (Genetta et al., 1994 ) (see Figure 1a) .
To test the hypothesis that USF prevents TFE-3 from activation, IgH reporter plasmids were cotransfected into non B-cells with expression plasmids encoding Vp16-TFE-3, dominant negative alleles of USF-1 and/or the B-cell speci®c co-activator, E47. In the absence of E47, Vp16-TFE-3 failed to activate a reporter plasmid (wt IgH) which carried four copies of the E3, E2 and E5 E-boxes of the IgH enhancer ( Figure 5, upper panel) . In contrast, a reporter, which contained only the TFE-3/USF/Myc-binding site (E3 only IgH), was eciently activated by Vp16-TFE-3 ( Figure 5, upper panel) . Co-expression of E47 allowed Vp16-TFE-3 to activate the full-length IgH enhancer, whereas it had little stimulatory eect on transactivation of the E3 only reporter by Vp16-TFE-3. Activation required binding of Vp16-TFE-3 to the IgH enhancer as a mutant lacking the TFE-3 binding site was not activated by Vp16-TFE-3 either in the presence or absence of E47; instead moderate repression was observed ( Figure 5 , middle panels).
Expression of a dominant negative allele of USF-1 (USF-1mutbr) alone did not aect enhancer activity, but synergized with Vp16-TFE-3 in inducing reporter activity ( Figure 5, upper panel) . This co-operation required the TFE-3 binding site (E3), since USF1mutbr and Vp16-TFE-3 did not activate a reporter construct where this site was mutated (mutE3IgH). In contrast to the wt IgH enhancer, USFmutbr stimulated activation by Vp16-TFE-3 less than twofold when assayed on the E3 only reporter, or when assayed on the wt IgH enhancer in the presence of E47 ( Figure 5 , lower panel). The data support the view that DNA binding by USF has a major role in determining the speci®c activation of the IgH enhancer.
If USF plays a general role in limiting transactivation of E-box dependent target genes, which are important for cell growth, one might expect TFE-3 to be mitogenic in the presence of dominant negative (Figure 6a) . Microinjection of either control plasmid or of plasmids encoding USF-1, TFE-3, USF-1mutbr, Max or Maxmutbr did not signi®cantly aect cyclin A expression in serum-starved RAT1 cells. Ectopic expression of Myc stimulated about 50% of successfully injected cells to express cyclin A. Co-expression of TFE-3 with a dominant negative allele of USF-1, but not with wt USF-1, stimulated cyclin A expression to a similar degree as expression of Myc. Co-expression of either Max or Maxmutbr with TFE-3 did not stimulate expression.
To con®rm that these results re¯ected bona ®de S phase entry, we examined the eects of TFE-3 and USF-1mutbr after transient transfection in serumstarved NIH3T3 cells since transfection eciencies were low in RAT1 cells (data not shown). Whereas transfection of TFE-3 or USF-1mutbr alone had minimal eects on the cell cycle, there was an increase in cells in S/G2/M phase upon co-transfection of TFE-3 and USF-1mutbr, consistent with their co-operative eects on cyclin A expression. Similarly, cells coexpressing Myc and Max showed a large increase in cells in S/G2/M phases of the cell cycle. The data demonstrate a physiological role for USF in restricting the mitogenic potential of TFE-3. Attempts to show that TFE-3 transforms primary rat embryo ®broblasts in combination with dominant negative alleles of USF-1 or alters the growth properties of RAT1 cells upon retroviral infection were not successful, potentially due to the much lower expression levels of dominant negative USF-1 achieved in these experiments (A Kiermaier, data not shown; C Cerni and B LuÈ scher, unpublished observations).
Since USF limits the transactivating and growth regulatory potential of Myc-related factors such as TFE-3, it was possible that this control was relaxed during cell immortalization. TFE-3 is known to be expressed in B-cells and these cells are immortalized with high eciency by Epstein-Barr virus (EBV). Therefore, we examined expression and binding activity of USF in primary human B-lymphocytes and their EBV-immortalized counterparts, lymphoblastoid cell lines (LCLs). When nuclear extracts prepared from peripheral resting B-cells and LCLs were examined for binding to a CACGTG E-box sequence (MB2) in an electrophoretic mobility shift assay (EMSA), we detected six major complexes (I ± VI) ( Figure 7a ). Competition experiments demonstrated that, with the exception of complex V, all complexes were E-box speci®c (Figure 7b ). Identical competition results were obtained using extracts prepared from primary B-cells (not shown).
To identify the components of the E-box binding factors detected in B-cells, speci®c antibodies were included in the EMSA reactions. Addition of a control preimmune serum did not signi®cantly aect the EMSA pattern (Figure 7c) . By contrast, addition of an anti-Max antiserum specifically disrupted or`supershifted' complexes I and VI. Inclusion of a Mnt-speci®c antibody disrupted complex I, but not VI. We concluded that complex I consists of a Mnt/Max heterodimer and complex VI of Max/Max homodimers. No alteration of the gel shift patterns was observed when either a c-Myc speci®c antibody or antibodies speci®c for Mad proteins were included in the EMSA reaction. Addition of an antibody that recognizes both USF-1 and USF-2 (a-USF) speci®cally disrupts complex IV (Figure 7c) . Also, antibodies that speci®cally recognize either USF-1 or -2 isoforms completely supershifted complex IV. Two other complexes (II and III) could not be identi®ed due to the lack of speci®c antibodies but may well contain TFE-3 and/or TFEB, since both proteins are expressed in B-cells.
Comparison between primary B-cells and LCLs (Figure 7a ) demonstrated that USF was the major complex in primary B-cells and that binding activity was signi®cantly reduced in immortalized LCLs. Similarly, Max/Max complex binding was also downregulated in LCLs relative to primary B-cells. By contrast, the Mnt/Max binding was not signi®cantly altered. Complex II was detected in primary B-cells, but not LCLs, and complex III (which migrates slightly faster) was detected in LCLs but not primary B-cells.
To determine the level at which DNA binding by USF and Max is modulated, steady state expression levels of Max, USF-1 and USF-2 were determined in RIPA lysates by Western blotting (Figure 7d ). Max was modestly downregulated in LCLs relative to primary B-cells; however, it does not appear that the downregulation of steady state levels of Max is sucient to account for downregulation of Max/Max homodimers. Two forms of Max were detected which may correspond to the prototypical and D9 splice forms. We suggest, therefore, that Max is additionally sequestered into other complexes in LCLs. Similarly, steady state levels of USF proteins were not signi®cantly altered. Similar results were obtained when nuclear extracts were examined for Max, USF-1 and -2; therefore dierences in extraction to not account for dierences in binding activity observed in primary B-cells and LCLs (data not shown). Therefore, modulation of USF DNA binding occurs at a posttranslational level (see Discussion).
To test whether downregulation of USF activity is an important event during B-cell immortalization, we generated an immortal B-cell line that conditionally overexpressed USF-1. DG75 cells (derived from an EBVnegative Burkitt lymphoma) were transfected with a plasmid that expresses an USF-1 cDNA under the control of a metallothionein promoter. Drug-resistant pools were isolated and single cell clones generated by dilution cloning. Immunoblot and EMSA analysis demonstrated increased USF-1 expression and USF DNA binding activity in cadmium treated USF-1, but not control clones (Figure 8a ). Supershift analysis showed that the induced binding activity was largely composed of USF-1/USF-2 heterodimers, similar to the endogenous USF complex in B-cells (not shown).
Control (vector only) and USF-1 inducible clones were plated at equal density in the absence or presence of cadmium and cell number determined up to 7 days. Control clones and clones expressing USF-1 grew at approximately the same rate in the absence of cadmium and attained similar saturation densities (Figure 8b ). There was a modest inhibition of cell growth by cadmium in all clones; however, the cell growth of USF-1 clones was signi®cantly reduced relative to control clones in the presence of cadmium. This reduction was not due to increased apoptosis, as no signi®cant cell death was observed at any time point when cells were examined by Trypan blue exclusion (cell viability was always 490%). Therefore, overexpression of USF-1 retards proliferation of immortal B-cell lines and prevents them from reaching their normal saturation density. The data strongly support the view that downregulation of DNA binding of USF activity is important for the immortalization of B-cells.
Discussion
In this report we provide evidence that DNA binding by USF is required for speci®c E-box dependent gene (7). Cells were collected 8 h later and assayed for protein expression by Western blotting with a-USF-1 antibodies and for MB2-binding activity by EMSA. (b) DG75 cell derived clones carrying pMEP4 (MEP5.1, MEP5.2) or pMEP4USF-1 (MEPUSF-13.1, MEPUSF-13.2) were diluted to 2610 5 cells per ml. Cell number was determined in control cultures or cultures exposed to 5 mM CdCl 2 for up to 7 days. Standard errors are derived from duplicate cultures and errors below 2610 4 cells per ml are now shown activation in vivo. First, the inability of TFE-3 to activate expression of a target gene of Myc (even when provided with a potent activation domain) is abolished when the TFE/USF-binding site is replaced by a GAL4-binding site. Second, USF binds to a Mycregulated E-box in vivo. Third, inhibition of USF binding allows TFE-3 to activate a Myc-dependent Ebox element and to promote S phase entry of quiescent cells. Fourth, dominant negative alleles of USF relieve the B-cell speci®city of activation of the IgH enhancer by TFE-3. Fifth, USF is downregulated during immortalization of B-cells and re-expression of USF-1 impairs proliferation of an immortalized B-cell line.
A number of previous reports has suggested a regulatory role for USF in transformation by Myc. For example, ectopic expression of USF-1 has been found to inhibit transformation of rat embryo ®broblasts by Myc and ras-oncogenes and to retard proliferation of HeLa cells; in both cases, an intact DNA binding domain is required for inhibition (Aperlo et al., 1996; Luo and Sawadogo, 1996) . Taken together with our ®ndings, the data suggest a model in which cellular levels of USF set a threshold against which dierent E-box binding proteins compete for activation. Lowering the threshold by ectopic expression of dominant negative alleles of USF generates a state in which proteins like TFE-3 can activate target genes that are normally kept inaccessible by USF, such as prothymosin-a and the immunoglobulin enhancer in non B-cells. Since dominant negative alleles of USF enable TFE-3 to promote S phase entry, USF may also have a related activity on genes that mediate the mitogenic properties of Myc. Similarly, we suggest that downregulation of USF during immortalization of Bcells relaxes the stringent control of E-box dependent transcription such that other E-box binding proteins like TFE-3 can contribute to transactivation of target genes of Myc in immortal B-cells. Our ®ndings are consistent with the observation that USF binds to the Myc regulated E-box of the CAD gene in vivo (Boyd et al., 1998) . The data do not address the molecular mechanism by which DNA binding by USF is regulated; however, several previous reports have shown that DNA binding of USF proteins is regulated by phosphorylation (Berger et al., 1998; Maekawa et al., 1991) and that the extent of phosphorylation is lower in established cell lines relative to primary cells (Galibert et al., 1997) .
We have been unable to detect any eect of dominant negative alleles of USF on gene activation by Myc or repression by Mad (A Kiermaier unpublished). The ®ndings suggest that levels of USF do not regulate access of Myc/Max to E-boxes in vivo. It is likely that this dierence between TFE-3 and Myc/ Max is at least in part due to a dierence in binding anities to DNA (L Desbarats, unpublished) . However, TFE-3 is even more potent than Myc/Max heterodimers in activation of synthetic reporter constructs (Moriizumi et al., 1998) or in the presence of dominant negative alleles of USF-1 (Figure 4) , demonstrating that dierences in anity to DNA are not sucient to explain the dierent behaviour in vivo. Clearly, therefore, discrimination between TFE-3 and Myc/Max heterodimers is a property of complex enhancers, not of isolated E-box elements.
Our data strongly suggest that stabilization of USF binding by factors binding to additional sites in these enhancers is critical for inhibition of transactivation by TFE-3. Similar interactions have also been described for the HIV-enhancer and the CIITA promoter, where binding of ets-1 or stat-1, respectively, to their cognate binding sites stabilizes binding of USF-1 to an adjacent Ebox element (Figure 9 ) (Muhlethaler-Mottet et al., 1998; Sieweke et al., 1998) . On both genes, USF-1 alone has no eect on gene expression, but synergizes with ets-1 and stat-1 in activation. Whether the outcome is synergistic activation or inhibition of TFE-3 dependent activation, this is most likely to result from synergistic binding to DNA. The list of examples also suggests that there may be a number of dierent, gene-speci®c transcription factors that interact with USF both for activation and inhibition of transactivation by TFE-3.
Materials and methods

Transfections and cell culture
HeLa, NIH3T3 and RAT1 cells were maintained and transfected as described (Desbarats et al., 1996) . LCLs and DG75 cells (Ben-Bassat et al., 1977) were maintained in RPMI 1640 (Gibco) supplemented with 15% (v/v) heatinactivated foetal calf serum (FCS; PAA Laboratories). Primary B-lymphocytes were isolated as previously described (Sinclair and Farrell, 1995) . FACSscan analysis was performed on transiently transfected NIH3T3 cells as described before (Peukert et al., 1997) .
IgH enhancer reporter plasmids and CMV-E47 were generously provided by Tom Kadesch and have been described (Carter et al., 1997) , prothymosin receptor constructs are described elsewhere (Gaubatz et al., 1995) . Details of the construction of the Gal4-E2 and Gal4-mutE2 and the mutE1/mutE2 reporter plasmids, and of the expression plasmids expressing Vp16-TFE-3, USF-1mutbr, USF-1Dbr, MaxDbr, Maxmutbr and USF-1 in an inducible manner will be provided upon request.
Antibodies
The following antibodies were used: rabbit anti-Max antibody (Upstate Biotechnology Inc.); rabbit anti-USF-1 antibody (IgGM), a rabbit anti-USF-2a/2b antibody (IgGG), a rabbit anti-USF-2a-speci®c antibody (IgGO) (Viollet et al., 1996) ; rabbit anti-Mnt antibody (#6823) (kind gift of Dr RN Eisenman, Seattle, WA, USA); rabbit anti-USF antibody which recognizes all USF-1 and USF-2 proteins (kind gift of Dr M Sawadogo, Houston, TX, USA). Nuclear extracts and electrophoretic mobility shift assays (EMSA) Nuclear extracts were prepared as described before (Gaubatz et al., 1995) . Double stranded oligonucleotides used for EMSA analyses (top strand only shown) include MB2 5'-AGG GGA CAC GTG GCC CGG-; MB2.M1 (mutant Ebox) 5'-AGG GAC ACC TGG CCC GG- (Bello Fernandez et al., 1993) ; P9599 5' -GTG TAA ACA CGC CGT GGG AAA AA-and kB (Promega) 5'-AGT TGA GGGGAC TTT CCC AGG-.
In-vivo crosslink experiments
Crosslinking and immune-precipitations were carried out according to (Boyd et al., 1998) from 3610 8 Rat1MycER cells. Precipitated DNA fragments were analysed by PCR with the following primers corresponding to rat prothymosina intron I sequence: 5'-CCT GCG TCG GAC CCC ATT GCA CCC GTT CCG CCC-; 5' nested: -GGT GCC GAA GCC CGG GGG AGT GGG TGG GGG CGG-; 3': -CCC CGG TGA CTT AAC GCC GGA CGT TGC GCG CC-.
